Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




AI Model Accurately Predicts MSI Tumor and Immune Checkpoint Inhibitor Responsiveness

By LabMedica International staff writers
Posted on 06 Aug 2025

One in three people is expected to develop cancer in their lifetime, and a key factor in patient prognosis is the tumor’s microsatellite status—whether it is stable or shows microsatellite instability-high (MSI-H). More...

MSI-H tumors are associated with better outcomes and are more responsive to immune checkpoint inhibitors (ICIs) compared to microsatellite stable cancers. These tumors, often deficient in mismatch repair proteins, do not necessarily respond well to traditional chemotherapeutics. As a result, experts recommend MSI testing for all newly diagnosed gastric and colorectal cancer patients. While artificial intelligence (AI) has been explored to streamline MSI testing, previous deep learning models have struggled with uncertainty in prediction and failed to deliver insights into ICI responsiveness. Now, a new AI model for accurate MSI prediction as well as immune checkpoint inhibitor responsiveness prediction is expected to help battle gastric and colorectal cancers and further cancer research in general.

A team of researchers from the US and Korea, including from Yonsei University College of Medicine (Seoul, South Korea) and Gangnam Severance Hospital (Seoul, South Korea), has developed MSI-SEER, a deep Gaussian process-based Bayesian model. This AI model analyzes hematoxylin and eosin-stained whole-slide images using a weakly supervised learning framework to predict MSI status in gastric and colorectal cancers. A standout feature of MSI-SEER is its ability to assess its own predictive confidence using Monte Carlo dropout to calculate predictive variance. This is then converted into a Bayesian Confidence Score (BCS), enabling the model to quantify the reliability of each prediction. When uncertainty is high, the system automatically flags those cases for manual review by human pathologists instead of making an autonomous decision. In addition to MSI prediction, the model also incorporates stroma-to-tumor ratio data to improve accuracy in predicting patient responsiveness to ICIs.

Moreover, MSI-SEER’s tile-level predictions reveal the spatial distribution of MSI-H regions within the tumor microenvironment, offering valuable insights into treatment response. The model was extensively validated using large datasets that included patients from diverse racial backgrounds. The findings, published in npj Digital Medicine, showed that MSI-SEER achieved state-of-the-art performance in MSI prediction by integrating uncertainty estimation. The system also proved highly effective in forecasting ICI responsiveness. These results suggest strong potential for real-world applications, such as in prospective cohort surveillance or as part of post-market (Phase IV) clinical trials. Beyond its immediate predictive power, the innovation points toward a broader future where AI can analyze multi-modal clinical data to support precision oncology. The researchers aim to further refine the model and explore wider clinical deployment.

“We believe our technology already has potential for real-world application as a form of prospective cohort surveillance, or a kind of Phase IV clinical trials,” said Prof. Jae-Ho Cheong, Yonsei University College of Medicine. “The longer-term implication of this study is that it is not about a single specific predictive AI model. Rather, it has a broader implication of how AI algorithm can analyze clinical multi-modal data and create clinically usable models for precision cancer medicine.”

Related Links:
Yonsei University College of Medicine


New
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
New
Clinical Chemistry System
P780
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A simple blood sample that allows DNA methylation could identify epigenetic biomarkers (Photo courtesy of 123RF)

Simple Blood Sample Could Identify Epigenetic Biomarkers to Predict CVD Risk in Type 2 Diabetes

People with type 2 diabetes face up to four times higher risk of cardiovascular events such as heart attacks, strokes, and angina compared to individuals without the condition. Yet, current tools used... Read more

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Microbiology

view channel
Image: MycoMEIA Aspergillus Assay is the first FDA-cleared urine-based test for invasive aspergillosis (Photo courtesy of Pearl Diagnostics)

Urine-Based Assay Diagnoses Common Lung Infection in Immunocompromised People

Invasive Aspergillosis (IA), a life-threatening fungal infection, poses a serious threat to immunocompromised individuals, especially those with hematologic malignancies, transplants, or severe lung diseases.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.